Maximizing Uptake of Core Products and Accelerating New Product Uptake

「As a result, sales of the core products Beova, a treatment for overactive bladder, Lasvic, a new quinolone antibacterial drug, Flutiform, a combination asthma treatment, and Desalex, an allergy treatment, increased.」

「Sales of the core products Beova, a treatment for overactive bladder, Lasvic, a new quinolone antibacterial drug, Flutiform, a combination asthma treatment, and Desalex, an allergy treatment, increased. Lyfnua, a cough treatment for which the prescription-day restriction was lifted in May 2023, also contributed to increased sales.」

「As a result, sales of the core products Beova, a treatment for overactive bladder, Lasvic, a new quinolone antibacterial drug, Flutiform, a combination asthma treatment, and Desalex, an allergy treatment, increased. Lyfnua, a cough treatment for which the prescription-day restriction was lifted in May 2023, also contributed to increased sales.」

「As a result, the core products Beova, a treatment for overactive bladder, and Lasvic, a new quinolone antibacterial drug, posted substantial growth. Lyfnua, a cough treatment for which the prescription-day restriction was lifted in May 2023, also contributed to increased sales.」

「As a result, the core products Beova, a treatment for overactive bladder, and Lasvic, a new quinolone antibacterial drug, grew. Lyfnua, a cough treatment for which the prescription-day restriction was lifted in May 2023, also contributed to increased sales.」

「As a result, sales grew for Beova, a treatment for overactive bladder whose restricted shipments were lifted in August 2022, as well as for the core products Desalex, an allergy treatment, and Lasvic, a new quinolone antibacterial drug.」

「For Lyfnua, a selective P2X3 receptor antagonist and cough treatment newly launched in April 2022, the Company provided information mainly to respiratory specialists to promote understanding of the product's characteristics.」

「For Jimso Bladder Instillation Solution 50%, a treatment for interstitial cystitis newly launched in April 2021, the Company provided information mainly to urology specialists in an effort to achieve market penetration.」

「The core products Beova, a treatment for overactive bladder, Desalex, an allergy treatment, and Lasvic, a new quinolone antibacterial drug, grew.」

「The core products Beova, a treatment for overactive bladder, Desalex, an allergy treatment, and Lasvic Tablets, a new quinolone oral antibacterial drug, grew. However, sales of Uritos, a long-listed treatment for overactive bladder, and Eyefargan, a licensed-out treatment for glaucoma and ocular hypertension, among others, declined. Sales in Japan of new drugs and other products were ¥16.820 billion, compared with ¥17.010 billion in the same period of the previous year.」

「The core products Beova, a treatment for overactive bladder, and Desalex, an allergy treatment, grew, while sales of Rubista, an environmental disinfectant and cleaning agent, increased amid the spread of COVID-19. On the other hand, sales of long-listed products such as Kipres, a treatment for bronchial asthma and allergic rhinitis, and Mucodyne, an airway mucus regulator and mucosal normalizer, declined. Sales of Nasonex, a metered-dose allergy rhinitis treatment for which an authorized generic was launched by Kyorin Remedio Co., Ltd., and Uritos, a treatment for overactive bladder, also declined.」

「The core products Beova, a treatment for overactive bladder, and Desalex, an allergy treatment, grew. However, Lasvic Tablets, a quinolone oral antibacterial drug newly launched in January 2020, continued to face challenges in market penetration because of the suspension of MR activities at medical institutions and other factors.」

「The core products Beova, a treatment for overactive bladder, and Desalex, an allergy treatment, grew. However, Lasvic Tablets, a quinolone oral antibacterial drug newly launched in January 2020, faced challenges in market penetration because MR activities at medical institutions were suspended.」

「The combination asthma treatment Flutiform grew steadily, and sales of Beova, the selective β3-adrenergic receptor agonist for overactive bladder for which long-term prescriptions became possible from December 2019 following the lifting of the prescription-duration restriction for new drugs, substantially exceeded the previous period. In addition, the quinolone oral antibacterial drug KRP-AM1977X (product name: Lasvic Tablets 75mg) was newly launched in January 2020.」

「The combination asthma treatment Flutiform grew steadily, and sales of Beova, the selective β3-adrenergic receptor agonist for overactive bladder for which long-term prescriptions became possible from December 2019 following the lifting of the prescription-duration restriction for new drugs, substantially exceeded the same period of the previous year.」

「The combination asthma treatment Flutiform grew steadily, and sales of Beova, the selective β3-adrenergic receptor agonist for overactive bladder launched in November 2018, also increased. In addition, Nasonex Nasal Spray, a metered-dose allergy rhinitis treatment whose sales were transferred from MSD K.K. in August of the same year, contributed to sales growth.」

「The combination asthma treatment Flutiform grew steadily, and sales of Beova, the selective β3-adrenergic receptor agonist for overactive bladder launched in November 2018, also increased. In addition, Nasonex Nasal Spray, a metered-dose allergy rhinitis treatment whose sales were transferred from MSD K.K. in August of the same year, contributed to sales growth.」

「In FY2018, the Company began sales of Nasonex, a metered-dose treatment for allergic rhinitis, and Beova, its internally developed new drug for overactive bladder.」

「The Company worked to maximize adoption of its core products, and the combination asthma treatment Flutiform grew steadily. In addition, sales of Nasonex Nasal Spray, a metered-dose allergy rhinitis treatment launched in August 2018 under an agreement concerning exclusive domestic sales rights with an affiliate of MSD K.K., and Beova, the long-awaited new selective β3-adrenergic receptor agonist for overactive bladder launched in November of the same year, contributed to growth in sales of new drugs.」

「The Company worked to maximize adoption of its core products, the combination asthma treatment Flutiform and the allergy treatment Desalex, and both products grew. It also began sales in August 2018 of Nasonex Nasal Spray, a metered-dose allergy rhinitis treatment, under an agreement concerning exclusive domestic sales rights with an affiliate of MSD K.K., and」

「To achieve the medium-term management plan's stated key strategy of increasing the share of new products, the Company worked to maximize adoption of its core products, the combination asthma treatment Flutiform and the allergy treatment Desalex, and both products grew.」

「The Company worked to increase the number of patients prescribed the combination asthma treatment Flutiform. For Desalex, an allergy treatment for which long-term prescriptions became possible in December 2017 following the lifting of the prescription-duration restriction for new drugs, it focused on market penetration and expanding prescription volume. As a result, both products posted substantial growth.」

「To achieve the key strategy in the medium-term management plan of increasing the share of new products, the Company worked to maximize adoption of its core products and accelerate uptake of new products. For the combination asthma treatment Flutiform, it sought to increase the number of patients receiving prescriptions. For Desalex, an allergy treatment for which long-term prescriptions became possible in December 2017 following the lifting of the prescription-duration restriction for new drugs, it focused on market penetration and expanding prescriptions. As a result, both products grew as expected.」

「We worked to expand prescriptions for Flutiform, a combination treatment for asthma, and Desalex, an allergy treatment newly launched in November 2016, and both products grew as expected」

「We worked to maximise the uptake of existing key products and ensure the early penetration of the characteristics of new products. This fiscal year, we launched Desalex tablets 5 mg, an allergy treatment, in November 2016,」

「As a new product, the Company launched Desalex tablets 5 mg, an allergy treatment, in November 2016. Kyorin Pharmaceutical Co., Ltd. has entered into a basic memorandum of understanding with Kaken Pharmaceutical Co., Ltd. for co-promotion of this drug to dermatologists and dermatology institutions, and the two companies are working to maximise its uptake. Kyorin Pharmaceutical Co., Ltd. has also entered into a co-promotion agreement with MSD K.K. for Nasonex nasal spray 50 μg, a metered-dose treatment for allergic rhinitis manufactured and marketed by MSD K.K., and began promotional activities in November 2016.」

「In addition to working to maximise the uptake of existing key products, we are taking steps to ensure the early penetration of the characteristics of new products targeted for launch during the period of the new medium-term management plan, "HOPE100—Stage 2—," and to build early momentum following their launch.」

「In response to changes in the medical and market environments, we are working to maximize uptake of existing core products and taking steps to ensure the early uptake of new products targeted for launch during the new medium-term management plan, “HOPE100 – Stage 2 –.”」